HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsu, Y.-M. Articles by Thomas, D. Search for Related Content PubMed PubMed Citation Articles by Hsu, Y.-M. Articles by Thomas, D. Social Bookmarking                      What's this?

Volume 272, Number 2, Issue of January 10, 1997 pp. 911-915
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Heteromultimeric Complexes of CD40 Ligand Are Present on the Cell Surface of Human T Lymphocytes

(Received for publication, September 24, 1996, and in revised form, November 19, 1996)

From the Departments of Protein Engineering, Molecular Genetics, and Immunology and Inflammation, Biogen Inc., Cambridge, Massachusetts 02142

CD40 ligand (CD40L), a 33-kDa type II membrane glycoprotein expressed primarily on activated CD4⁺ T lymphocytes, is responsible for the helper function of T cells on resting B cells in a non-antigen-dependent, non-major histocompatability complex-restricted fashion. Interaction of CD40L with its receptor CD40 induces proliferation of and isotype switching in B lymphocytes. Recently we solved the x-ray structure of recombinant soluble CD40L and showed that, similar to other members of the tumor necrosis factor family, CD40L indeed exists as a trimer. We now report that, under normal physiological conditions, CD40L molecules exist as heteromultimeric complexes. These CD40L complexes, made of the full length and smaller fragments of CD40L, are present on the cell surface of T lymphocytes and are capable of interacting with CD40 molecule. A prominent fragment with a mass of 31 kDa accounts for as much as half of the CD40L on the surface of Jurkat cells. N-terminal sequence data revealed that this fragment lacks the cytoplasmic tail. A minor 18-kDa fragment of CD40L was also characterized which lacks the cytoplasmic tail, transmembrane region, and stalk region of the extracellular domain. The presence of CD40L heteromultimeric variants implies an additional regulation of the functional activity of this ligand complex.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. Hanawa, Y. Ma, S. A. Mikolajczak, M. L. Charles, T. Yoshida, R. Yoshida, C. A. Strathdee, D. W. Litchfield, and A. Ochi A novel costimulatory signaling in human T lymphocytes by a splice variant of CD28 Blood, March 15, 2002; 99(6): 2138 - 2145. [Abstract] [Full Text] [PDF]

				S. Imai, H. Tezuka, Y. Furuhashi, R. Muto, and K. Fujita A Factor of Inducing IgE from a Filarial Parasite Is an Agonist of Human CD40 J. Biol. Chem., November 30, 2001; 276(49): 46118 - 46124. [Abstract] [Full Text] [PDF]

				B. Berner, G. Wolf, K. M Hummel, G. A Müller, and M. A Reuss-Borst Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis Ann Rheum Dis, March 1, 2000; 59(3): 190 - 195. [Abstract] [Full Text]

				E. Garber, L. Su, B. Ehrenfels, M. Karpusas, and Y.-M. Hsu CD154 Variants Associated with Hyper-IgM Syndrome Can Form Oligomers and Trigger CD40-mediated Signals J. Biol. Chem., November 19, 1999; 274(47): 33545 - 33550. [Abstract] [Full Text] [PDF]

				K. Seyama, W. R. A. Osborne, and H. D. Ochs CD40 Ligand Mutants Responsible for X-linked Hyper-IgM Syndrome Associate with Wild Type CD40 Ligand J. Biol. Chem., April 16, 1999; 274(16): 11310 - 11320. [Abstract] [Full Text] [PDF]

				J. Suttles, D. M. Milhorn, R. W. Miller, J. C. Poe, L. M. Wahl, and R. D. Stout CD40 Signaling of Monocyte Inflammatory Cytokine Synthesis through an ERK1/2-dependent Pathway. A TARGET OF INTERLEUKIN ()-4 AND IL-10 ANTI-INFLAMMATORY ACTION J. Biol. Chem., February 26, 1999; 274(9): 5835 - 5842. [Abstract] [Full Text] [PDF]

				Y. Chicheportiche, P. R. Bourdon, H. Xu, Y.-M. Hsu, H. Scott, C. Hession, I. Garcia, and J. L. Browning TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis J. Biol. Chem., December 19, 1997; 272(51): 32401 - 32410. [Abstract] [Full Text] [PDF]

				L. Su, E. A. Garber, and Y.-M. Hsu CD154 Variant Lacking Tumor Necrosis Factor Homologous Domain Inhibits Cell Surface Expression of Wild-type Protein J. Biol. Chem., January 12, 2001; 276(3): 1673 - 1676. [Abstract] [Full Text] [PDF]